Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

Treatment of latent TB is an important public-health strategy, but 9 months of daily isoniazid (270 doses) poses challenges for compliance. In this study, 3 months of weekly isoniazid plus rifapentine (12 doses) was found to be noninferior to 9 months of isoniazid alone. Tuberculosis results in near...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 365; no. 23; pp. 2155 - 2166
Main Authors:	Sterling, Timothy R, Villarino, M. Elsa, Borisov, Andrey S, Shang, Nong, Gordin, Fred, Bliven-Sizemore, Erin, Hackman, Judith, Hamilton, Carol Dukes, Menzies, Dick, Kerrigan, Amy, Weis, Stephen E, Weiner, Marc, Wing, Diane, Conde, Marcus B, Bozeman, Lorna, Horsburgh, C. Robert, Chaisson, Richard E
Format:	Journal Article
Language:	English
Published:	Waltham, MA Massachusetts Medical Society 08.12.2011
Subjects:	Adult Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Bacterial diseases Biological and medical sciences Directly Observed Therapy Drug Administration Schedule Drug Therapy, Combination Follow-Up Studies General aspects Hepatotoxicity HIV Human bacterial diseases Human immunodeficiency virus Humans Infections Infectious diseases Intention to Treat Analysis Isoniazid Isoniazid - administration & dosage Isoniazid - adverse effects Male Medical sciences Middle Aged Motivation Pharmacology. Drug treatments Prospective Studies Rifampin - administration & dosage Rifampin - adverse effects Rifampin - analogs & derivatives Risk Factors Self Administration Skin Tuberculosis Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis - prevention & control Tuberculosis and atypical mycobacterial infections Virus Latency Infection Medicine Antituberculous agent Antibacterial agent Isoniazid Rifapentine
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Treatment of latent TB is an important public-health strategy, but 9 months of daily isoniazid (270 doses) poses challenges for compliance. In this study, 3 months of weekly isoniazid plus rifapentine (12 doses) was found to be noninferior to 9 months of isoniazid alone. Tuberculosis results in nearly 2 million deaths annually worldwide. 1 More than 2 billion persons are infected with Mycobacterium tuberculosis, 2 and from this reservoir active tuberculosis will develop in millions of persons in coming decades. Treatment of latent M. tuberculosis infection among the persons at highest risk for progression to active disease is an important strategy for tuberculosis control and elimination. 3 – 6 The current standard regimen for the treatment of latent M. tuberculosis infection is 9 months of daily isoniazid. 3 The efficacy for isoniazid was found to be 69 to 93% in a study that was published in 1982 (before the . . .
AbstractList	Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.BACKGROUNDTreatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.METHODSWe conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.In the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P=0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001).RESULTSIn the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P=0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001).The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.).CONCLUSIONSThe use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.). Treatment of latent TB is an important public-health strategy, but 9 months of daily isoniazid (270 doses) poses challenges for compliance. In this study, 3 months of weekly isoniazid plus rifapentine (12 doses) was found to be noninferior to 9 months of isoniazid alone. Tuberculosis results in nearly 2 million deaths annually worldwide. 1 More than 2 billion persons are infected with Mycobacterium tuberculosis, 2 and from this reservoir active tuberculosis will develop in millions of persons in coming decades. Treatment of latent M. tuberculosis infection among the persons at highest risk for progression to active disease is an important strategy for tuberculosis control and elimination. 3 – 6 The current standard regimen for the treatment of latent M. tuberculosis infection is 9 months of daily isoniazid. 3 The efficacy for isoniazid was found to be 69 to 93% in a study that was published in 1982 (before the . . . Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion. We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%. In the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P=0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001). The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.). BackgroundTreatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of isoniazid for 9 months is efficacious but is limited by toxicity and low rates of treatment completion.MethodsWe conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis. Subjects were enrolled from the United States, Canada, Brazil, and Spain and followed for 33 months. The primary end point was confirmed tuberculosis, and the noninferiority margin was 0.75%.ResultsIn the modified intention-to-treat analysis, tuberculosis developed in 7 of 3986 subjects in the combination-therapy group (cumulative rate, 0.19%) and in 15 of 3745 subjects in the isoniazid-only group (cumulative rate, 0.43%), for a difference of 0.24 percentage points. Rates of treatment completion were 82.1% in the combination-therapy group and 69.0% in the isoniazid-only group (P<0.001). Rates of permanent drug discontinuation owing to an adverse event were 4.9% in the combination-therapy group and 3.7% in the isoniazid-only group (P=0.009). Rates of investigator-assessed drug-related hepatotoxicity were 0.4% and 2.7%, respectively (P<0.001).ConclusionsThe use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing tuberculosis and had a higher treatment-completion rate. Long-term safety monitoring will be important. (Funded by the Centers for Disease Control and Prevention; PREVENT TB ClinicalTrials.gov number, NCT00023452.)
Author	Bliven-Sizemore, Erin Wing, Diane Horsburgh, C. Robert Weiner, Marc Menzies, Dick Conde, Marcus B Kerrigan, Amy Chaisson, Richard E Borisov, Andrey S Bozeman, Lorna Weis, Stephen E Villarino, M. Elsa Hamilton, Carol Dukes Sterling, Timothy R Shang, Nong Hackman, Judith Gordin, Fred
Author_xml	– sequence: 1 givenname: Timothy R surname: Sterling fullname: Sterling, Timothy R – sequence: 2 givenname: M. Elsa surname: Villarino fullname: Villarino, M. Elsa – sequence: 3 givenname: Andrey S surname: Borisov fullname: Borisov, Andrey S – sequence: 4 givenname: Nong surname: Shang fullname: Shang, Nong – sequence: 5 givenname: Fred surname: Gordin fullname: Gordin, Fred – sequence: 6 givenname: Erin surname: Bliven-Sizemore fullname: Bliven-Sizemore, Erin – sequence: 7 givenname: Judith surname: Hackman fullname: Hackman, Judith – sequence: 8 givenname: Carol Dukes surname: Hamilton fullname: Hamilton, Carol Dukes – sequence: 9 givenname: Dick surname: Menzies fullname: Menzies, Dick – sequence: 10 givenname: Amy surname: Kerrigan fullname: Kerrigan, Amy – sequence: 11 givenname: Stephen E surname: Weis fullname: Weis, Stephen E – sequence: 12 givenname: Marc surname: Weiner fullname: Weiner, Marc – sequence: 13 givenname: Diane surname: Wing fullname: Wing, Diane – sequence: 14 givenname: Marcus B surname: Conde fullname: Conde, Marcus B – sequence: 15 givenname: Lorna surname: Bozeman fullname: Bozeman, Lorna – sequence: 16 givenname: C. Robert surname: Horsburgh fullname: Horsburgh, C. Robert – sequence: 17 givenname: Richard E surname: Chaisson fullname: Chaisson, Richard E
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25267878$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22150035$$D View this record in MEDLINE/PubMed
BookMark	eNp10U1r3DAQBmBRUpLNx7HXIgolJzf6tKxjCUm6yW4CYXM2sjxitdjSVrIPza-Pl2xTGshcdJhHw8vMMToIMQBCXyj5QYksL-6vbpfRUEpEpeQnNKOS80IIUh6gGSGsKoTS_Agd57whU1GhD9ERY1QSwuUM3a3WCQAvYxjWGUeHH70zWwiDD4BNaPE8x-DNs2-xiwkvzDD18GpsINmxi9lnPA8O7OBjOEWfnekynO3fE_R0fbW6_FUsHm7mlz8XhRWVGAqmrSLQlm0LjtB2Ck5ES6m1qlGs1NqxylSNtAxYaRXVhCkGVcMMswK0BH6Czl_nblP8PUIe6t5nC11nAsQx15pSzRXX1SS_vZObOKYwhZsQYVIqvkNf92hsemjrbfK9SX_qv0uawPc9MNmaziUTrM__nGSlqtRuUPHqbIo5J3BvhJJ6d6z6v2NNnr_z1g9mt8khGd99-Gufpu9zHWDTf-BeAILEoOY
CODEN	NEJMAG
CitedBy_id	crossref_primary_10_1186_s12916_017_0865_x crossref_primary_10_1159_000360183 crossref_primary_10_1093_milmed_usaa414 crossref_primary_10_1016_j_cll_2014_02_007 crossref_primary_10_1016_S2352_4642_19_30337_2 crossref_primary_10_1097_EDE_0000000000001418 crossref_primary_10_1136_bmjopen_2019_033945 crossref_primary_10_1183_13993003_02502_2019 crossref_primary_10_1183_13993003_03028_2020 crossref_primary_10_3389_fphar_2023_1153815 crossref_primary_10_1093_cid_ciz438 crossref_primary_10_1093_jac_dky403 crossref_primary_10_1186_s12889_021_10733_9 crossref_primary_10_2105_AJPH_2014_301897 crossref_primary_10_1016_S0140_6736_15_00323_2 crossref_primary_10_1016_j_thorsurg_2018_09_010 crossref_primary_10_1136_bmjgh_2018_001135 crossref_primary_10_1093_cid_ciaa827 crossref_primary_10_1097_TP_0000000000001329 crossref_primary_10_1016_j_jgar_2022_04_025 crossref_primary_10_17269_s41997_019_00240_1 crossref_primary_10_1097_TP_0000000000000133 crossref_primary_10_1097_TP_0000000000001224 crossref_primary_10_1038_s41598_021_97444_8 crossref_primary_10_1097_MCP_0000000000000045 crossref_primary_10_1093_milmed_usaa300 crossref_primary_10_1002_jia2_25629 crossref_primary_10_1080_24745332_2017_1387879 crossref_primary_10_1128_AAC_05128_14 crossref_primary_10_1016_j_bbrc_2018_02_030 crossref_primary_10_1016_j_ijid_2022_02_033 crossref_primary_10_1016_j_ejmech_2014_08_066 crossref_primary_10_1016_j_genhosppsych_2013_03_018 crossref_primary_10_1093_cid_ciae183 crossref_primary_10_1016_j_lanwpc_2021_100229 crossref_primary_10_1111_jgs_14752 crossref_primary_10_1136_thoraxjnl_2015_207915 crossref_primary_10_1038_s41467_020_20731_x crossref_primary_10_1093_infdis_jir886 crossref_primary_10_1002_jia2_25623 crossref_primary_10_1080_17476348_2016_1267572 crossref_primary_10_1093_cid_ciy230 crossref_primary_10_1007_s11904_012_0120_1 crossref_primary_10_1371_journal_pone_0256043 crossref_primary_10_1016_j_ijmyco_2015_05_004 crossref_primary_10_2471_BLT_16_170167 crossref_primary_10_1016_S1473_3099_13_70128_2 crossref_primary_10_1093_ofid_ofae180 crossref_primary_10_1586_eog_12_35 crossref_primary_10_1016_j_chom_2016_04_001 crossref_primary_10_1183_13993003_01363_2018 crossref_primary_10_1016_S2352_3018_25_00002_5 crossref_primary_10_1186_s43058_021_00173_2 crossref_primary_10_1371_journal_pone_0213524 crossref_primary_10_1080_14787210_2023_2207820 crossref_primary_10_3389_fpubh_2015_00191 crossref_primary_10_1038_s41591_022_02136_z crossref_primary_10_1093_cid_ciad083 crossref_primary_10_1007_s15010_017_1004_5 crossref_primary_10_5588_ijtldopen_24_0305 crossref_primary_10_1371_journal_pmed_1004356 crossref_primary_10_1080_24745332_2020_1728712 crossref_primary_10_1097_FPC_0000000000000417 crossref_primary_10_3389_fphar_2024_1463575 crossref_primary_10_1007_s40265_024_02131_3 crossref_primary_10_1111_1756_185X_12708 crossref_primary_10_1080_14656566_2016_1215428 crossref_primary_10_1097_PHH_0000000000000261 crossref_primary_10_1128_AAC_01705_21 crossref_primary_10_1186_s12879_018_3468_z crossref_primary_10_2188_jea_JE20120216 crossref_primary_10_1186_1471_2458_14_22 crossref_primary_10_5588_ijtldopen_23_0609 crossref_primary_10_1016_j_ijid_2020_05_009 crossref_primary_10_1097_QAI_0000000000003301 crossref_primary_10_1164_rccm_201908_1606OC crossref_primary_10_1097_MCP_0b013e328351f9d6 crossref_primary_10_1513_AnnalsATS_201312_420PS crossref_primary_10_1016_j_clp_2024_08_012 crossref_primary_10_1016_j_ijtb_2020_09_028 crossref_primary_10_1016_S1473_3099_12_70275_X crossref_primary_10_1186_s12916_016_0610_x crossref_primary_10_3390_ijerph17010210 crossref_primary_10_1128_CMR_00039_14 crossref_primary_10_1172_JCI161564 crossref_primary_10_1016_j_jiph_2020_03_013 crossref_primary_10_1128_microbiolspec_TNMI7_0034_2016 crossref_primary_10_3390_ijms23158531 crossref_primary_10_7326_M14_2082 crossref_primary_10_7759_cureus_38182 crossref_primary_10_1016_S0140_6736_16_30769_3 crossref_primary_10_1002_sim_8777 crossref_primary_10_1016_j_cmi_2024_08_024 crossref_primary_10_1097_COH_0000000000000517 crossref_primary_10_1097_COH_0000000000000879 crossref_primary_10_1097_QCO_0000000000000629 crossref_primary_10_1016_S2213_2600_24_00083_3 crossref_primary_10_3390_microorganisms11030743 crossref_primary_10_3390_pathogens11020128 crossref_primary_10_1111_hiv_13487 crossref_primary_10_1186_s12879_019_4557_3 crossref_primary_10_1038_pr_2016_205 crossref_primary_10_1080_17512433_2016_1222270 crossref_primary_10_1007_s40506_014_0031_3 crossref_primary_10_1186_s12981_016_0118_7 crossref_primary_10_1016_j_tube_2021_102127 crossref_primary_10_1093_cid_cis732 crossref_primary_10_1080_17512433_2017_1366311 crossref_primary_10_7326_ANNALS_24_00870 crossref_primary_10_1128_AAC_02184_20 crossref_primary_10_1517_14656566_2012_657176 crossref_primary_10_1016_j_tmaid_2016_05_010 crossref_primary_10_1164_rccm_201907_1289OC crossref_primary_10_1016_j_cmi_2020_06_008 crossref_primary_10_1016_S2213_2600_23_00096_6 crossref_primary_10_1080_14787210_2018_1483238 crossref_primary_10_1513_AnnalsATS_201402_065OC crossref_primary_10_1513_AnnalsATS_202009_1153OC crossref_primary_10_1038_s41598_020_69228_z crossref_primary_10_1371_journal_pone_0214532 crossref_primary_10_1128_JCM_00393_20 crossref_primary_10_1186_s13063_022_06296_8 crossref_primary_10_1007_s11908_019_0662_0 crossref_primary_10_1186_s12879_021_05766_9 crossref_primary_10_1038_nrd4001 crossref_primary_10_1097_IPC_0000000000000518 crossref_primary_10_1186_s13012_020_01025_8 crossref_primary_10_1177_1060028019888855 crossref_primary_10_1002_ebch_1962 crossref_primary_10_2196_jmir_9825 crossref_primary_10_1080_17425255_2020_1758060 crossref_primary_10_1097_GRF_0000000000000483 crossref_primary_10_1164_rccm_201809_1623ED crossref_primary_10_1093_jac_dkt483 crossref_primary_10_1097_TP_0000000000002014 crossref_primary_10_1016_j_ccm_2019_07_008 crossref_primary_10_1164_rccm_201203_0494UP crossref_primary_10_3390_biomedicines9091209 crossref_primary_10_1016_j_bjid_2017_10_001 crossref_primary_10_1016_j_jfma_2020_10_008 crossref_primary_10_3390_tropicalmed3040115 crossref_primary_10_1128_microbiolspec_TNMI7_0039_2016 crossref_primary_10_1111_ctr_13513 crossref_primary_10_1183_13993003_01616_2018 crossref_primary_10_1136_annrheumdis_2018_213097 crossref_primary_10_7759_cureus_25083 crossref_primary_10_1177_1753465813503028 crossref_primary_10_1001_jamainternmed_2017_3941 crossref_primary_10_1542_peds_2014_3958 crossref_primary_10_1134_S1068162023603257 crossref_primary_10_1164_rccm_201911_2258ED crossref_primary_10_1007_s13312_019_1503_9 crossref_primary_10_1016_j_jpba_2014_11_011 crossref_primary_10_1016_j_fct_2017_01_016 crossref_primary_10_1371_journal_pone_0253159 crossref_primary_10_2105_AJPH_2018_304529 crossref_primary_10_3892_ol_2014_2180 crossref_primary_10_1183_13993003_04438_2020 crossref_primary_10_1371_journal_pone_0155968 crossref_primary_10_1186_1471_2466_14_133 crossref_primary_10_1111_apt_16952 crossref_primary_10_1371_journal_pone_0048900 crossref_primary_10_1183_20734735_0149_2021 crossref_primary_10_1097_QAD_0000000000001098 crossref_primary_10_1016_j_rmed_2019_10_005 crossref_primary_10_1016_j_jdcr_2017_11_020 crossref_primary_10_1016_S1473_3099_17_30692_8 crossref_primary_10_1056_NEJMc1200489 crossref_primary_10_1016_j_tube_2017_11_009 crossref_primary_10_3201_eid3103_240633 crossref_primary_10_1093_cid_ciae101 crossref_primary_10_1111_ajt_12100 crossref_primary_10_1016_j_jinf_2018_07_003 crossref_primary_10_1093_cid_ciad251 crossref_primary_10_3390_tropicalmed9020029 crossref_primary_10_1080_17425255_2018_1416093 crossref_primary_10_1016_S1473_3099_15_00007_9 crossref_primary_10_1177_247553031319a00205 crossref_primary_10_1186_s12879_021_06637_z crossref_primary_10_3201_eid1903_121521 crossref_primary_10_1186_s12879_022_07465_5 crossref_primary_10_1016_j_tube_2017_07_011 crossref_primary_10_1097_COH_0000000000000495 crossref_primary_10_1371_journal_pone_0218373 crossref_primary_10_1093_cid_ciad246 crossref_primary_10_1111_ajt_15841 crossref_primary_10_1186_1471_2334_12_107 crossref_primary_10_1093_cid_ciad245 crossref_primary_10_1164_rccm_202006_2144ED crossref_primary_10_1183_13993003_01756_2020 crossref_primary_10_1371_journal_pone_0065276 crossref_primary_10_1093_infdis_jiad425 crossref_primary_10_1097_INF_0000000000001164 crossref_primary_10_1128_MMBR_00010_14 crossref_primary_10_17816_EID448391 crossref_primary_10_1111_jgs_14696 crossref_primary_10_1148_rg_2017160032 crossref_primary_10_1017_ice_2018_219 crossref_primary_10_1016_j_chphi_2024_100508 crossref_primary_10_1177_2055217317752202 crossref_primary_10_3390_tropicalmed9010004 crossref_primary_10_1016_j_ccm_2013_02_003 crossref_primary_10_1056_NEJMoa1714284 crossref_primary_10_1016_j_arbres_2019_07_009 crossref_primary_10_1056_NEJMoa1714283 crossref_primary_10_1111_tid_13244 crossref_primary_10_1186_s12889_022_14766_6 crossref_primary_10_3390_microorganisms10122334 crossref_primary_10_1016_j_ijtb_2020_10_006 crossref_primary_10_1016_j_rce_2015_09_005 crossref_primary_10_1093_cid_ciy082 crossref_primary_10_1056_NEJMra1200894 crossref_primary_10_1183_13993003_01470_2018 crossref_primary_10_1097_PHH_0000000000001077 crossref_primary_10_1136_bmjopen_2020_047514 crossref_primary_10_1136_thoraxjnl_2016_209579 crossref_primary_10_1542_peds_2021_054663 crossref_primary_10_1016_j_biotechadv_2016_05_007 crossref_primary_10_1586_eri_12_150 crossref_primary_10_7759_cureus_50581 crossref_primary_10_1016_j_lpm_2022_104112 crossref_primary_10_1016_j_pulmoe_2019_11_010 crossref_primary_10_1016_S0140_6736_12_60727_2 crossref_primary_10_1186_s12916_021_01968_9 crossref_primary_10_1378_chest_12_0142 crossref_primary_10_1513_AnnalsATS_201908_623OC crossref_primary_10_3389_fmed_2023_1265057 crossref_primary_10_1016_j_ijid_2020_03_010 crossref_primary_10_1093_ofid_ofw082 crossref_primary_10_1586_14787210_2016_1173541 crossref_primary_10_1016_j_ijid_2016_11_006 crossref_primary_10_3390_ijms222413317 crossref_primary_10_1183_09031936_00205512 crossref_primary_10_1097_MAJ_0b013e318285f7db crossref_primary_10_2105_AJPH_2018_304606 crossref_primary_10_1164_rccm_201501_0069OC crossref_primary_10_1371_journal_pone_0211688 crossref_primary_10_1371_journal_pone_0254211 crossref_primary_10_1093_jpids_pit077 crossref_primary_10_15585_mmwr_rr6901a1 crossref_primary_10_1016_j_chest_2015_11_017 crossref_primary_10_1016_j_ijid_2021_02_107 crossref_primary_10_3390_jcm8060812 crossref_primary_10_1186_s12889_025_23750_9 crossref_primary_10_1513_AnnalsATS_201509_632PS crossref_primary_10_1371_journal_pone_0030194 crossref_primary_10_1056_NEJMp1501316 crossref_primary_10_1007_s40475_018_0139_5 crossref_primary_10_1371_journal_pone_0138349 crossref_primary_10_1016_j_rceng_2015_11_001 crossref_primary_10_1093_cid_ciac248 crossref_primary_10_1111_resp_13078 crossref_primary_10_1016_j_arbr_2019_07_006 crossref_primary_10_1136_bmjopen_2021_057717 crossref_primary_10_1164_rccm_201505_0863ED crossref_primary_10_1093_ofid_ofab319 crossref_primary_10_1080_17512433_2017_1259066 crossref_primary_10_3201_eid2504_171630 crossref_primary_10_1097_INF_0000000000001151 crossref_primary_10_1016_j_ajic_2015_03_035 crossref_primary_10_1093_cid_ciaa1364 crossref_primary_10_1093_cid_ciaa1482 crossref_primary_10_1097_COH_0000000000000009 crossref_primary_10_1155_2012_874083 crossref_primary_10_3390_tropicalmed8020089 crossref_primary_10_1146_annurev_med_040717_051150 crossref_primary_10_1016_j_tube_2012_06_004 crossref_primary_10_1080_14787210_2018_1513324 crossref_primary_10_3390_tropicalmed8120520 crossref_primary_10_2105_AJPH_2013_301637 crossref_primary_10_1080_24745332_2023_2226004 crossref_primary_10_2147_IDR_S304799 crossref_primary_10_1007_s10405_013_0696_1 crossref_primary_10_1093_cid_civ611 crossref_primary_10_1016_j_jval_2025_03_009 crossref_primary_10_1038_nm0713_798b crossref_primary_10_1056_NEJMp1707387 crossref_primary_10_1186_s12916_020_01651_5 crossref_primary_10_1111_cts_12810 crossref_primary_10_1038_s41598_019_47645_z crossref_primary_10_1080_22423982_2020_1758501 crossref_primary_10_1371_journal_pmed_1002814 crossref_primary_10_1371_journal_pone_0276387 crossref_primary_10_1016_j_eimce_2017_11_021 crossref_primary_10_1186_s12879_017_2245_8 crossref_primary_10_1097_INF_0000000000004767 crossref_primary_10_1056_NEJMra1008049 crossref_primary_10_1093_cid_ciaa286 crossref_primary_10_1186_s12879_025_10832_7 crossref_primary_10_3390_pathogens11111258 crossref_primary_10_7326_M20_7577 crossref_primary_10_1093_infdis_jiy265 crossref_primary_10_1007_s11538_024_01285_1 crossref_primary_10_3390_jcm10071376 crossref_primary_10_1016_j_ijid_2020_02_015 crossref_primary_10_1185_03007995_2012_747952 crossref_primary_10_5888_pcd17_190263 crossref_primary_10_1164_rccm_201806_1053PP crossref_primary_10_1002_cpt_1221 crossref_primary_10_1186_s12916_023_02785_y crossref_primary_10_1371_journal_pone_0222810 crossref_primary_10_1183_09031936_00198813 crossref_primary_10_1016_j_amepre_2018_04_030 crossref_primary_10_1093_jpids_piac047 crossref_primary_10_12688_f1000research_7403_1 crossref_primary_10_1093_cid_ciad301 crossref_primary_10_1186_s12889_015_1600_1 crossref_primary_10_1111_resp_12598 crossref_primary_10_1093_cid_civ991 crossref_primary_10_1128_CMR_00035_19 crossref_primary_10_1016_j_diagmicrobio_2014_04_005 crossref_primary_10_1093_jpids_pit030 crossref_primary_10_1016_j_pedhc_2015_02_002 crossref_primary_10_1016_S1473_3099_18_30110_5 crossref_primary_10_7326_M21_3170 crossref_primary_10_1016_j_eimc_2025_06_002 crossref_primary_10_1136_bmjopen_2025_100927 crossref_primary_10_1093_cid_ciad659 crossref_primary_10_1093_cid_ciae508 crossref_primary_10_1097_PHH_0000000000000822 crossref_primary_10_3390_tropicalmed4040133 crossref_primary_10_1016_j_ajem_2019_12_040 crossref_primary_10_1001_jama_2023_3954 crossref_primary_10_1080_1744666X_2019_1705785 crossref_primary_10_1136_bmjresp_2018_000341 crossref_primary_10_1183_09031936_00080212 crossref_primary_10_1080_17441692_2021_1892793 crossref_primary_10_1002_acr_22061 crossref_primary_10_1093_cid_civ766 crossref_primary_10_2217_fvl_2020_0009 crossref_primary_10_1056_NEJMoa1813060 crossref_primary_10_1007_s13312_015_0648_4 crossref_primary_10_1111_tid_12580 crossref_primary_10_1517_13543784_2016_1121993 crossref_primary_10_1002_pds_4423 crossref_primary_10_1016_j_jiph_2025_102917 crossref_primary_10_1111_resp_13346 crossref_primary_10_1097_MD_0000000000004126 crossref_primary_10_1016_j_nurpra_2014_10_018 crossref_primary_10_1093_cid_ciac672 crossref_primary_10_1016_j_arbr_2018_01_032 crossref_primary_10_1002_sscp_202300130 crossref_primary_10_1183_13993003_02359_2021 crossref_primary_10_4103_ijmr_IJMR_1901_18 crossref_primary_10_1016_j_lpm_2017_01_015 crossref_primary_10_1093_infdis_jiae237 crossref_primary_10_1186_s12889_021_12142_4 crossref_primary_10_1093_ofid_ofaa144 crossref_primary_10_1007_s40265_022_01817_w crossref_primary_10_1371_journal_pmed_1003703 crossref_primary_10_1080_14787210_2018_1521269 crossref_primary_10_1007_s12098_018_02854_8 crossref_primary_10_1111_tid_12436 crossref_primary_10_1128_AAC_01125_12 crossref_primary_10_1111_resp_12002 crossref_primary_10_1093_cid_cix725 crossref_primary_10_1186_1471_2458_13_894 crossref_primary_10_1038_srep30781 crossref_primary_10_1007_s00508_022_02009_y crossref_primary_10_17269_cjph_104_3643 crossref_primary_10_1093_cid_cit488 crossref_primary_10_1164_rccm_202006_2488ED crossref_primary_10_1186_s12879_017_2377_x crossref_primary_10_1186_s12879_016_1550_y crossref_primary_10_1517_17425247_2014_877886 crossref_primary_10_1093_cid_ciab209 crossref_primary_10_1128_microbiolspec_TNMI7_0028_2016 crossref_primary_10_1093_aje_kwab150 crossref_primary_10_3109_00365548_2014_989540 crossref_primary_10_1093_cid_ciz1157 crossref_primary_10_1586_14787210_2013_851600 crossref_primary_10_1093_aje_kwz147 crossref_primary_10_1111_resp_12156 crossref_primary_10_5500_wjt_v14_i3_96225 crossref_primary_10_1056_NEJMcp2108501 crossref_primary_10_1186_s12916_021_02189_w crossref_primary_10_21292_2075_1230_2018_96_12_55_61 crossref_primary_10_1164_rccm_201903_0646OC crossref_primary_10_1590_0037_8682_0156_2014 crossref_primary_10_1056_NEJMra1405427 crossref_primary_10_1128_aac_01297_22 crossref_primary_10_1371_journal_pone_0207582 crossref_primary_10_1186_s12890_020_01274_9 crossref_primary_10_1093_cid_cix505 crossref_primary_10_1371_journal_pone_0295048 crossref_primary_10_1111_dth_14512 crossref_primary_10_1093_ije_dyac045 crossref_primary_10_1093_cid_civ323 crossref_primary_10_1093_cid_cit027 crossref_primary_10_1186_s13690_023_01098_z crossref_primary_10_1080_24745332_2022_2039498 crossref_primary_10_1093_ofid_ofad219 crossref_primary_10_1111_phn_12170 crossref_primary_10_1007_s40336_016_0164_0 crossref_primary_10_1007_s40471_016_0076_6 crossref_primary_10_1146_annurev_med_100622_024848 crossref_primary_10_1586_14787210_2014_880338 crossref_primary_10_1056_NEJMe1312301 crossref_primary_10_1093_infdis_jiae180 crossref_primary_10_1097_COH_0b013e328354bd44 crossref_primary_10_1371_journal_pmed_1002882 crossref_primary_10_3389_fmicb_2022_821066 crossref_primary_10_1016_j_ijid_2024_02_004 crossref_primary_10_1016_S0140_6736_23_01379_X crossref_primary_10_1186_s12916_022_02378_1 crossref_primary_10_1128_AAC_01124_13 crossref_primary_10_1093_cid_ciz819 crossref_primary_10_1128_JCM_01347_19 crossref_primary_10_1183_13993003_01733_2023 crossref_primary_10_1371_journal_pone_0250387 crossref_primary_10_1016_S1473_3099_17_30248_7 crossref_primary_10_1111_resp_12054 crossref_primary_10_1183_09031936_00214014 crossref_primary_10_1080_14787210_2018_1519393 crossref_primary_10_1007_s10405_012_0647_2 crossref_primary_10_1016_j_pulmoe_2019_06_002 crossref_primary_10_1001_jama_2022_24362 crossref_primary_10_1164_rccm_202112_2866ED crossref_primary_10_3390_jcm13123563 crossref_primary_10_1016_j_ijid_2019_07_004 crossref_primary_10_1177_0033354919826557 crossref_primary_10_1016_S2352_3018_20_30032_1 crossref_primary_10_1002_ddr_70109 crossref_primary_10_1080_22221751_2023_2169195 crossref_primary_10_1016_j_puhe_2025_105774 crossref_primary_10_1016_j_tube_2018_05_013 crossref_primary_10_1016_S1473_3099_25_00083_0 crossref_primary_10_1016_j_respe_2022_09_074 crossref_primary_10_1093_aje_kwz172 crossref_primary_10_1093_cid_civ464 crossref_primary_10_1186_s12889_018_5393_x crossref_primary_10_1186_s12889_015_2530_7 crossref_primary_10_1097_TP_0b013e3182a94a2f crossref_primary_10_1093_cid_civ582 crossref_primary_10_1177_20499361221084163 crossref_primary_10_1371_journal_pmed_1003875 crossref_primary_10_1080_24745332_2022_2133030 crossref_primary_10_1371_journal_pone_0036001 crossref_primary_10_1542_pir_2018_0093 crossref_primary_10_1371_journal_pone_0298628 crossref_primary_10_1016_j_rmed_2019_09_004 crossref_primary_10_1136_archdischild_2013_303876 crossref_primary_10_1055_a_1934_8303 crossref_primary_10_14745_ccdr_v43i34a02 crossref_primary_10_1177_2333794X20981548 crossref_primary_10_14745_ccdr_v43i34a01 crossref_primary_10_1371_journal_pone_0134597 crossref_primary_10_1513_AnnalsATS_202005_574RL crossref_primary_10_1111_j_1365_3156_2012_03053_x crossref_primary_10_1371_journal_pone_0215322 crossref_primary_10_1080_22221751_2025_2502010 crossref_primary_10_1097_MOP_0000000000000049 crossref_primary_10_1093_cid_ciy987 crossref_primary_10_1177_0033354920927845 crossref_primary_10_1164_rccm_202003_0761LE crossref_primary_10_15585_mmwr_rr6907a1 crossref_primary_10_4103_lungindia_lungindia_336_23 crossref_primary_10_1371_journal_pone_0318209 crossref_primary_10_1007_s11845_020_02209_3 crossref_primary_10_1016_j_tube_2020_102041 crossref_primary_10_1016_S1473_3099_17_30447_4 crossref_primary_10_1097_QCO_0000000000001117 crossref_primary_10_1186_s41479_016_0019_5 crossref_primary_10_1016_j_arbres_2018_01_015 crossref_primary_10_1183_13993003_02180_2018 crossref_primary_10_1073_pnas_1121497109 crossref_primary_10_1172_JCI162688 crossref_primary_10_3390_ijerph17228342 crossref_primary_10_1093_ofid_ofaf563 crossref_primary_10_1097_QCO_0000000000000253 crossref_primary_10_1002_14651858_CD007545_pub2 crossref_primary_10_1164_rccm_201912_2489OC crossref_primary_10_1016_S0140_6736_13_62113_3 crossref_primary_10_1136_bmjopen_2021_055295 crossref_primary_10_1016_S2468_2667_24_00150_6 crossref_primary_10_1097_PHH_0000000000000893 crossref_primary_10_1016_j_lanwpc_2023_100770 crossref_primary_10_1590_0037_8682_0336_2015 crossref_primary_10_1016_j_prrv_2020_02_004 crossref_primary_10_1515_med_2021_0002 crossref_primary_10_1586_14787210_2016_1168693 crossref_primary_10_1016_j_ijid_2014_11_020 crossref_primary_10_1007_s40265_014_0222_8 crossref_primary_10_1177_0956462415619261 crossref_primary_10_1186_s12879_016_1549_4 crossref_primary_10_1016_j_bbrc_2020_09_140 crossref_primary_10_1093_ecco_jcc_jjab052 crossref_primary_10_1007_s11908_021_00756_z crossref_primary_10_1001_jamanetworkopen_2025_25207 crossref_primary_10_1111_j_1753_6405_2012_00895_x crossref_primary_10_1155_2022_9542756 crossref_primary_10_1186_s12916_021_02110_5 crossref_primary_10_1038_emi_2016_10 crossref_primary_10_1183_09031936_00000712 crossref_primary_10_1038_s41598_023_43310_8 crossref_primary_10_1111_tmi_13952 crossref_primary_10_1128_msystems_00616_25 crossref_primary_10_1097_QAI_0000000000001641 crossref_primary_10_1172_JCI137294 crossref_primary_10_1093_cid_ciaa1741 crossref_primary_10_1016_j_ijid_2022_01_063 crossref_primary_10_1111_resp_13737 crossref_primary_10_1016_j_ijtb_2020_07_017 crossref_primary_10_1056_NEJMc2502735 crossref_primary_10_3167_jla_2021_050103 crossref_primary_10_1016_j_diamond_2025_111995 crossref_primary_10_1016_j_ijbiomac_2024_132727 crossref_primary_10_1183_13993003_00577_2015 crossref_primary_10_1016_j_cmi_2024_06_024 crossref_primary_10_1016_S1473_3099_18_30787_4 crossref_primary_10_1056_NEJMc1508223 crossref_primary_10_1007_s00108_019_00685_z crossref_primary_10_1136_thoraxjnl_2015_207687 crossref_primary_10_2105_AJPH_2015_302662 crossref_primary_10_1016_S1473_3099_20_30914_2 crossref_primary_10_1093_cid_ciw126 crossref_primary_10_1097_QAD_0000000000003508 crossref_primary_10_1016_j_yapd_2015_04_001 crossref_primary_10_1056_NEJMe1111859 crossref_primary_10_1016_S1473_3099_19_30575_4 crossref_primary_10_1164_rccm_201308_1480OC crossref_primary_10_1016_S2213_8587_14_70109_3 crossref_primary_10_1097_JCMA_0000000000000605 crossref_primary_10_1111_1469_0691_12641 crossref_primary_10_1016_S2352_4642_21_00052_3 crossref_primary_10_1136_bmj_2023_077431 crossref_primary_10_1016_S2213_2600_24_00076_6 crossref_primary_10_1097_PHH_0000000000001211 crossref_primary_10_17269_s41997_021_00556_x crossref_primary_10_1093_cid_ciw376 crossref_primary_10_1016_S0140_6736_19_30024_8 crossref_primary_10_1038_s41598_022_22721_z crossref_primary_10_1111_imj_13601 crossref_primary_10_1111_jgh_14018 crossref_primary_10_1016_j_ejmech_2017_06_005 crossref_primary_10_1016_j_pop_2016_09_011 crossref_primary_10_3201_eid2803_212131 crossref_primary_10_1542_peds_2017_2838 crossref_primary_10_1016_j_cmi_2023_10_023 crossref_primary_10_1186_s12913_022_08855_w crossref_primary_10_1001_jama_2023_4899 crossref_primary_10_1016_j_jfma_2011_11_001 crossref_primary_10_1007_s10900_013_9704_y crossref_primary_10_1093_cid_ciaf069 crossref_primary_10_1038_s41598_023_44854_5 crossref_primary_10_1093_ofid_ofu120 crossref_primary_10_1177_1740774519885380 crossref_primary_10_1016_j_idc_2014_05_002 crossref_primary_10_2217_fmb_2016_0027 crossref_primary_10_1016_j_ijid_2022_02_047 crossref_primary_10_1016_S0140_6736_24_02479_6 crossref_primary_10_1002_jia2_25698 crossref_primary_10_1073_pnas_2207022119 crossref_primary_10_1002_jia2_25576 crossref_primary_10_1513_AnnalsATS_201704_326OC crossref_primary_10_1080_17476348_2017_1335599 crossref_primary_10_1016_j_jmii_2018_05_003 crossref_primary_10_1097_JOM_0000000000001904 crossref_primary_10_1080_23744235_2017_1377346 crossref_primary_10_1183_13993003_01245_2015 crossref_primary_10_1007_s11904_020_00529_8 crossref_primary_10_2217_fmb_2016_0131 crossref_primary_10_3201_eid2809_220092 crossref_primary_10_1007_s15010_013_0489_9 crossref_primary_10_1080_23744235_2018_1459046 crossref_primary_10_1093_ofid_ofv220 crossref_primary_10_3389_fimmu_2025_1494283 crossref_primary_10_2105_AJPH_2015_302895 crossref_primary_10_1007_s40506_017_0135_7 crossref_primary_10_1093_aje_kwu320 crossref_primary_10_1183_16000617_0044_2022 crossref_primary_10_1136_bmjopen_2021_050629 crossref_primary_10_1128_JCM_00427_18 crossref_primary_10_1093_infdis_jis034 crossref_primary_10_1146_annurev_publhealth_031912_114431 crossref_primary_10_3390_pathogens12050728 crossref_primary_10_1172_JCI173156
Cites_doi	10.1016/S0140-6736(97)06532-X 10.2165/00003088-200140050-00002 10.1164/rccm.200512-1953OC 10.1001/jama.283.11.1445 10.1164/rccm.200510-1563OC 10.1378/chest.09-0394 10.1164/ajrccm/148.6_Pt_1.1541 10.1016/S0002-9343(01)00695-7 10.1164/rccm.200901-0153OC 10.1001/jama.273.3.220 10.1164/ajrccm.161.supplement_3.ats600 10.1164/ajrccm.150.5.7952564 10.1056/NEJMsa031667 10.1056/NEJMoa1005136 10.1164/ajrccm.153.1.8542139 10.1001/jama.295.10.1152 10.1128/AAC.43.9.2126 10.1097/00002030-199818000-00014 10.1097/01.inf.0000214963.55217.9c 10.1097/MAJ.0b013e31814a586a 10.1016/S0140-6736(02)09742-8 10.1164/rccm.200303-390OC 10.7326/0003-4819-137-8-200210150-00007 10.1164/ajrccm/137.1.2 10.1164/arrd.1972.106.3.357 10.1016/S0140-6736(98)11467-8
ContentType	Journal Article
Contributor	Felix, Cristina Greenaway, Christina Kellert, Laurie Stevenson, Gloria Sanchez, Grace Valenzuela, Diana Mello, Fernanda C Q Hammock, Linda R Shang, Nong King, Barbara Burgess, Gerry Schluger, Neil W Tapy, Jan Grbic, Angela Escalante, Patricio Mota, Gisele Sacramento, Claudeci dos Santos Uribe, Juan Shafer, Norma de Oliveira, Valéria Rodriguez, Victoria Davis, Judy Anokute, Veronica Hackman, Judith Napolitano, Eileen Mannix, Sharyn Kritski, Afranio Schwartzman, Kevin Engle, Melissa Tracy, Mark Helal, Joseph Lozano, Vilma Efron, Anne Brassard, Paul Burzynski, Joseph Fortuna, Millene Barty S Arevalo, Bert Wing, Diane Conde, Marcus B West, Kevin B Luna, Laurie Oamar, Bonifacia Turk, Lee Cailleaux-Cezar, Michelle Jimenez, Jose A McSherry, George Burman, William Redd, Belinda Lardizabal, Alfred Sterling, Timothy R Wolk, Magda Guerra, Renata L Belknap, Robert Miller, Kathleen Horsburgh, Jr, C Robert Mangura, Bonita T Francisco, Peach Pavon, Hipolito Sterling, Timothy Luken, Celia Rayos, Ermelinda Weiner, Marc Chaisson, Richard E Lands, Larry Brown, Maria B
Contributor_xml	– sequence: 1 givenname: Timothy R surname: Sterling fullname: Sterling, Timothy R – sequence: 2 givenname: M Elsa surname: Villarino fullname: Villarino, M Elsa – sequence: 3 givenname: Andrey S surname: Borisov fullname: Borisov, Andrey S – sequence: 4 givenname: Nong surname: Shang fullname: Shang, Nong – sequence: 5 givenname: Fred surname: Gordin fullname: Gordin, Fred – sequence: 6 givenname: Awal surname: Khan fullname: Khan, Awal – sequence: 7 givenname: Judith surname: Hackman fullname: Hackman, Judith – sequence: 8 givenname: Carol Dukes surname: Hamilton fullname: Hamilton, Carol Dukes – sequence: 9 givenname: Dick surname: Menzies fullname: Menzies, Dick – sequence: 10 givenname: Amy surname: Kerrigan fullname: Kerrigan, Amy – sequence: 11 givenname: C Robert surname: Horsburgh, Jr fullname: Horsburgh, Jr, C Robert – sequence: 12 givenname: Richard E surname: Chaisson fullname: Chaisson, Richard E – sequence: 13 givenname: George surname: McSherry fullname: McSherry, George – sequence: 14 givenname: Bert surname: Arevalo fullname: Arevalo, Bert – sequence: 15 givenname: Stephen E surname: Weis fullname: Weis, Stephen E – sequence: 16 givenname: Michel surname: Fernandez fullname: Fernandez, Michel – sequence: 17 givenname: Barbara surname: King fullname: King, Barbara – sequence: 18 givenname: Lee surname: Turk fullname: Turk, Lee – sequence: 19 givenname: Norma surname: Shafer fullname: Shafer, Norma – sequence: 20 givenname: Gloria surname: Stevenson fullname: Stevenson, Gloria – sequence: 21 givenname: Guadalupe surname: Bayona fullname: Bayona, Guadalupe – sequence: 22 givenname: Randy surname: Dean fullname: Dean, Randy – sequence: 23 givenname: Joseph surname: Helal fullname: Helal, Joseph – sequence: 24 givenname: Gerry surname: Burgess fullname: Burgess, Gerry – sequence: 25 givenname: Marcus B surname: Conde fullname: Conde, Marcus B – sequence: 26 givenname: Fernanda C Q surname: Mello fullname: Mello, Fernanda C Q – sequence: 27 givenname: Anne surname: Efron fullname: Efron, Anne – sequence: 28 givenname: Carla surname: Loredo fullname: Loredo, Carla – sequence: 29 givenname: Millene Barty S surname: Fortuna fullname: Fortuna, Millene Barty S – sequence: 30 givenname: Michelle surname: Cailleaux-Cezar fullname: Cailleaux-Cezar, Michelle – sequence: 31 givenname: Renata L surname: Guerra fullname: Guerra, Renata L – sequence: 32 givenname: Gisele surname: Mota fullname: Mota, Gisele – sequence: 33 givenname: Cristina surname: Felix fullname: Felix, Cristina – sequence: 34 givenname: Afranio surname: Kritski fullname: Kritski, Afranio – sequence: 35 givenname: Valéria surname: de Oliveira fullname: de Oliveira, Valéria – sequence: 36 givenname: Claudeci dos Santos surname: Sacramento fullname: Sacramento, Claudeci dos Santos – sequence: 37 givenname: Richard surname: Wing fullname: Wing, Richard – sequence: 38 givenname: Diane surname: Wing fullname: Wing, Diane – sequence: 39 givenname: Diana surname: Valenzuela fullname: Valenzuela, Diana – sequence: 40 givenname: Josefina surname: Gonzalez fullname: Gonzalez, Josefina – sequence: 41 givenname: Juan surname: Uribe fullname: Uribe, Juan – sequence: 42 givenname: Brian R surname: Smith fullname: Smith, Brian R – sequence: 43 givenname: Marc surname: Weiner fullname: Weiner, Marc – sequence: 44 givenname: Melissa surname: Engle fullname: Engle, Melissa – sequence: 45 givenname: Jose A surname: Jimenez fullname: Jimenez, Jose A – sequence: 46 givenname: Hipolito surname: Pavon fullname: Pavon, Hipolito – sequence: 47 givenname: Victoria surname: Rodriguez fullname: Rodriguez, Victoria – sequence: 48 givenname: Kevin B surname: West fullname: West, Kevin B – sequence: 49 givenname: David surname: Dooley fullname: Dooley, David – sequence: 50 givenname: Duane surname: Hospenthal fullname: Hospenthal, Duane – sequence: 51 givenname: Timothy surname: Sterling fullname: Sterling, Timothy – sequence: 52 givenname: Linda R surname: Hammock fullname: Hammock, Linda R – sequence: 53 givenname: Belinda surname: Redd fullname: Redd, Belinda – sequence: 54 givenname: Ingrid surname: Montgomery fullname: Montgomery, Ingrid – sequence: 55 givenname: Kathleen surname: Miller fullname: Miller, Kathleen – sequence: 56 givenname: Brenda E surname: Jones fullname: Jones, Brenda E – sequence: 57 givenname: Patricio surname: Escalante fullname: Escalante, Patricio – sequence: 58 givenname: Peregrina surname: Molina fullname: Molina, Peregrina – sequence: 59 givenname: Claudia surname: Silva fullname: Silva, Claudia – sequence: 60 givenname: Angela surname: Grbic fullname: Grbic, Angela – sequence: 61 givenname: Maria surname: Brown fullname: Brown, Maria – sequence: 62 givenname: Bonifacia surname: Oamar fullname: Oamar, Bonifacia – sequence: 63 givenname: Ermelinda surname: Rayos fullname: Rayos, Ermelinda – sequence: 64 givenname: Celia surname: Luken fullname: Luken, Celia – sequence: 65 givenname: Neil W surname: Schluger fullname: Schluger, Neil W – sequence: 66 givenname: Joseph surname: Burzynski fullname: Burzynski, Joseph – sequence: 67 givenname: Vilma surname: Lozano fullname: Lozano, Vilma – sequence: 68 givenname: Magda surname: Wolk fullname: Wolk, Magda – sequence: 69 givenname: Bonita T surname: Mangura fullname: Mangura, Bonita T – sequence: 70 givenname: Lee B surname: Reichman fullname: Reichman, Lee B – sequence: 71 givenname: Alfred surname: Lardizabal fullname: Lardizabal, Alfred – sequence: 72 givenname: Maria Corazon surname: Leus fullname: Leus, Maria Corazon – sequence: 73 givenname: Marilyn surname: Owens fullname: Owens, Marilyn – sequence: 74 givenname: Eileen surname: Napolitano fullname: Napolitano, Eileen – sequence: 75 givenname: Laurie surname: Kellert fullname: Kellert, Laurie – sequence: 76 givenname: Veronica surname: Anokute fullname: Anokute, Veronica – sequence: 77 givenname: William surname: Burman fullname: Burman, William – sequence: 78 givenname: Randall surname: Reves fullname: Reves, Randall – sequence: 79 givenname: Robert surname: Belknap fullname: Belknap, Robert – sequence: 80 givenname: David surname: Cohn fullname: Cohn, David – sequence: 81 givenname: Jan surname: Tapy fullname: Tapy, Jan – sequence: 82 givenname: Grace surname: Sanchez fullname: Sanchez, Grace – sequence: 83 givenname: Laurie surname: Luna fullname: Luna, Laurie – sequence: 84 givenname: Antonino surname: Catanzaro fullname: Catanzaro, Antonino – sequence: 85 givenname: Philip surname: LoBue fullname: LoBue, Philip – sequence: 86 givenname: Kathleen surname: Moser fullname: Moser, Kathleen – sequence: 87 givenname: Mark surname: Tracy fullname: Tracy, Mark – sequence: 88 givenname: Peach surname: Francisco fullname: Francisco, Peach – sequence: 89 givenname: Judy surname: Davis fullname: Davis, Judy – sequence: 90 givenname: Richard I surname: Menzies fullname: Menzies, Richard I – sequence: 91 givenname: Kevin surname: Schwartzman fullname: Schwartzman, Kevin – sequence: 92 givenname: Christina surname: Greenaway fullname: Greenaway, Christina – sequence: 93 givenname: Larry surname: Lands fullname: Lands, Larry – sequence: 94 givenname: Sharyn surname: Mannix fullname: Mannix, Sharyn – sequence: 95 givenname: Paul surname: Brassard fullname: Brassard, Paul – sequence: 96 givenname: Bérénice surname: Mortezai fullname: Mortezai, Bérénice – sequence: 97 givenname: Barry surname: Rabinovitch fullname: Rabinovitch, Barry – sequence: 98 givenname: Marthe surname: Pelletier fullname: Pelletier, Marthe
Copyright	Copyright © 2011 Massachusetts Medical Society. All rights reserved. 2015 INIST-CNRS
Copyright_xml	– notice: Copyright © 2011 Massachusetts Medical Society. All rights reserved. – notice: 2015 INIST-CNRS
CorporateAuthor	TB Trials Consortium PREVENT TB Study Team
CorporateAuthor_xml	– name: TB Trials Consortium PREVENT TB Study Team
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8
DOI	10.1056/NEJMoa1104875
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Database eLibrary ProQuest Central (subscription) Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep (ProQuest) SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database ProQuest Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Psychology
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Proquest Nursing & Allied Health Source url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1533-4406
EndPage	2166
ExternalDocumentID	2533918191 22150035 25267878 10_1056_NEJMoa1104875 NJ201112083652306
Genre	Original Article Multicenter Study Research Support, U.S. Gov't, P.H.S Comparative Study Randomized Controlled Trial Journal Article
GroupedDBID	- 0R 0WA 123 186 1AW 1KJ 1VV 29N 2KS 2WC 34G 39C 3O- 3V. 4 4.4 53G 55 5D0 5RE 68V 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 8RP AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AASXA AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQES ABQIJ ABUFD ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ACVYA ADBBV ADCBC AENEX AETEA AFDAS AFFNX AFHKK AFKRA AGNAY AHMBA AHVBC AIKQT AJJEV AJYGW ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCR BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS EJD ET EX3 F20 F5P FD8 FM. FYUFA G8K GJ GNUQQ GUQSH H13 HCIFZ HZ IH2 K-O K78 KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC MVM N9A NEJ O0- O9- OK1 OMK OVD P-O P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TN5 TWZ U1N UCV UKR UMD UQL VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZKB ZR0 ZXP --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 1CY 36B 6TJ AAMNW AAYXX ABBLC ABCQX ABDPE ABDQB ABJNI ACKOT ACPFK ADRHT ADUKH ADXHL AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W NAPCQ PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ TEORI TUQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM 41~ 8WZ 9M8 A6W AAQOH AAUTI ABEFU ACPVT ACTDY AFFDN AFOSN AJUXI ALIPV D0S FA8 IQODW J5H LPU MQT NHB OHT QZG SKT UBX WHG XOL YHZ YQI YQJ YYQ ZGI AGFXO CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y PKEHL Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c484t-29c70ed6ddef01d04804d11cc7b72699f28a8b5c2e26c7190272e8b2a2c4e95e3
IEDL.DBID	M7P
ISICitedReferencesCount	728
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000297731400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0028-4793 1533-4406
IngestDate	Thu Sep 04 18:03:50 EDT 2025 Thu Nov 06 13:30:27 EST 2025 Wed Feb 19 01:49:21 EST 2025 Mon Jul 21 09:14:10 EDT 2025 Sat Nov 29 03:54:29 EST 2025 Tue Nov 18 21:55:33 EST 2025 Wed Nov 11 00:33:55 EST 2020
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	23
Keywords	Infection Medicine Antituberculous agent Antibacterial agent Isoniazid Rifapentine
Language	English
License	CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c484t-29c70ed6ddef01d04804d11cc7b72699f28a8b5c2e26c7190272e8b2a2c4e95e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://www.nejm.org/doi/pdf/10.1056/NEJMoa1104875?articleTools=true
PMID	22150035
PQID	910255738
PQPubID	40644
PageCount	12
ParticipantIDs	proquest_miscellaneous_911937398 proquest_journals_910255738 pubmed_primary_22150035 pascalfrancis_primary_25267878 crossref_primary_10_1056_NEJMoa1104875 crossref_citationtrail_10_1056_NEJMoa1104875 mms_nejm_10_1056_NEJMoa1104875
ProviderPackageCode	DCD 7FN
PublicationCentury	2000
PublicationDate	2011-12-08
PublicationDateYYYYMMDD	2011-12-08
PublicationDate_xml	– month: 12 year: 2011 text: 2011-12-08 day: 08
PublicationDecade	2010
PublicationPlace	Waltham, MA
PublicationPlace_xml	– name: Waltham, MA – name: United States – name: Boston
PublicationTitle	The New England journal of medicine
PublicationTitleAlternate	N Engl J Med
PublicationYear	2011
Publisher	Massachusetts Medical Society
Publisher_xml	– name: Massachusetts Medical Society
References	Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press, 2000. Baciewicz, AM, Chrisman, CR, Finch, CK, Self, TH (r038) 2008; 335 Horsburgh, CR (r008) 2004; 350 Global tuberculosis control 2010. Geneva: World Health Organization, 2010. Gordin, F, Chaisson, RE, Matts, JP (r014) 2000; 283 Garibaldi, RA, Drusin, RE, Ferebee, SH, Gregg, MB (r032) 1972; 106 Blake, MJ, Abdel-Rahman, SM, Jacobs, RF, Lowery, NK, Sterling, TR, Kearns, GL (r020) 2006; 25 Common toxicity criteria version 2.0. Bethesda, MD: Cancer Therapy Evaluation Program, 1999 ( ). (r029) 2001; 50 Horsburgh, CR, Goldberg, S, Bethel, J (r011) 2010; 137 Ji, B, Truffot-Pernot, C, LaCroix, C (r016) 1993; 148 Schechter, M, Zajdenverg, R, Falco, G (r027) 2006; 173 (r007) 1982; 60 Sterling, TR, Bethel, J, Goldberg, S, Weinfurter, P, Yun, L, Horsburgh, CR (r006) 2006; 173 (r023) 1976; 19 Sutherland I. The ten-year incidence of clinical tuberculosis following “conversion” in 2550 individuals aged 14 to 19 years: TSRU Progress Report. The Hague, the Netherlands: KNCV, 1968. Vernon, A, Burman, W, Benator, D, Khan, A, Bozeman, L (r033) 1999; 353 Chapuis, L, Ji, B, Truffot-Pernot, C, O'Brien, RJ, Raviglione, MC, Grosset, JH (r018) 1994; 150 Benator, D, Bhattacharya, M, Bozeman, L (r019) 2002; 360 (r003) 2000; 161 Martinson, NA, Barnes, GL, Moulton, LH (r028) 2011; 365 Raviglione, MC, Snider, DE, Kochi, A (r002) 1995; 273 Chaisson, RE, Link Barnes, G, Hackman, J (r035) 2001; 110 Miyazaki, E, Chaisson, RE, Bishai, WR (r017) 1999; 43 Mwinga, A, Hosp, M, Godfrey-Faussett, P (r013) 1998; 12 Burman, WJ, Gallicano, K, Peloquin, C (r037) 2001; 40 (r030) 2001; 50 Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011 ( ). Jasmer, RM, Saukkonen, JJ, Blumberg, HM (r015) 2002; 137 (r031) 2003; 52 Halsey, NA, Coberly, J, Desormeaux, J (r012) 1998; 351 Piaggio, G, Elbourne, DR, Altman, DG, Pocock, SJ, Evans, SJ (r026) 2006; 295 Holland, DP, Sanders, GD, Hamilton, CD, Stout, JE (r036) 2009; 179 Snider, DE (r025) 1988; 137 Kritski, AL, Marques, MJ, Rabahi, MF (r024) 1996; 153 LoBue, PA, Moser, KS (r010) 2003; 168 Comstock, GW (r034) 1999; 3 Jereb, J, Etkind, SC, Joglar, OT, Moore, M, Taylor, Z (r009) 2003; 7 Comstock GW (r034) 1999; 3 Chapuis L (r018) 1994; 150 r020 r001 r019 r013 r035 r014 r036 r037 r016 r038 Miyazaki E (r017) 1999; 43 r010 Garibaldi RA (r032) 1972; 106 r011 r033 r012 Jasmer RM (r015) 2002; 137 r006 r028 r008 r002 Jereb J (r009) 2003; 7 r025 r026 r005 r027 Kritski AL (r024) 1996; 153 22494127 - N Engl J Med. 2012 Apr 12;366(15):1447; author reply 1448 22150042 - N Engl J Med. 2011 Dec 8;365(23):2230-1 22494128 - N Engl J Med. 2012 Apr 12;366(15):1447-8; author reply 1448
References_xml	– volume: 19 start-page: 1 year: 1976 end-page: 63 ident: r023 article-title: Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. publication-title: Adv Tuberc Res – volume: 150 start-page: 1355 year: 1994 end-page: 1362 ident: r018 article-title: Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. publication-title: Am J Respir Crit Care Med – volume: 137 start-page: 2 year: 1988 end-page: 4 ident: r025 article-title: Decision analysis for isoniazid preventive therapy: take it or leave it? publication-title: Am Rev Respir Dis – volume: 137 start-page: 401 year: 2010 end-page: 409 ident: r011 article-title: Latent TB infection treatment acceptance and completion in the United States and Canada. publication-title: Chest – volume: 106 start-page: 357 year: 1972 end-page: 365 ident: r032 article-title: Isoniazid-associated hepatitis: report of an outbreak. publication-title: Am Rev Respir Dis – volume: 7 start-page: S384 year: 2003 end-page: S390 ident: r009 article-title: Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. publication-title: Int J Tuberc Lung Dis – volume: 60 start-page: 555 year: 1982 end-page: 564 ident: r007 article-title: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. publication-title: Bull World Health Organ – volume: 350 start-page: 2060 year: 2004 end-page: 2067 ident: r008 article-title: Priorities for the treatment of latent tuberculosis infection in the United States. publication-title: N Engl J Med – volume: 295 start-page: 1152 year: 2006 end-page: 1160 ident: r026 article-title: Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. publication-title: JAMA – volume: 52 start-page: 735 year: 2003 end-page: 739 ident: r031 article-title: Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection -- United States, 2003. publication-title: MMWR Morb Mortal Wkly Rep – volume: 50 start-page: 733 year: 2001 end-page: 735 ident: r030 article-title: Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations -- United States, 2001. publication-title: MMWR Morb Mortal Wkly Rep – volume: 110 start-page: 610 year: 2001 end-page: 615 ident: r035 article-title: A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. publication-title: Am J Med – volume: 273 start-page: 220 year: 1995 end-page: 226 ident: r002 article-title: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. publication-title: JAMA – volume: 40 start-page: 327 year: 2001 end-page: 341 ident: r037 article-title: Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. publication-title: Clin Pharmacokinet – volume: 25 start-page: 405 year: 2006 end-page: 409 ident: r020 article-title: Pharmacokinetics of rifapentine in children. publication-title: Pediatr Infect Dis J – reference: Common toxicity criteria version 2.0. Bethesda, MD: Cancer Therapy Evaluation Program, 1999 ( ). – reference: Sutherland I. The ten-year incidence of clinical tuberculosis following “conversion” in 2550 individuals aged 14 to 19 years: TSRU Progress Report. The Hague, the Netherlands: KNCV, 1968. – volume: 43 start-page: 2126 year: 1999 end-page: 2130 ident: r017 article-title: Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. publication-title: Antimicrob Agents Chemother – volume: 351 start-page: 786 year: 1998 end-page: 792 ident: r012 article-title: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. publication-title: Lancet – volume: 50 start-page: 289 year: 2001 end-page: 291 ident: r029 article-title: Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection -- New York and Georgia, 2000. publication-title: MMWR Morb Mortal Wkly Rep – volume: 161 start-page: S221 year: 2000 end-page: S247 ident: r003 article-title: Targeted tuberculin testing and treatment of latent tuberculosis infection. publication-title: Am J Respir Crit Care Med – volume: 3 start-page: 847 year: 1999 end-page: 850 ident: r034 article-title: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? publication-title: Int J Tuberc Lung Dis – volume: 365 start-page: 11 year: 2011 end-page: 20 ident: r028 article-title: New regimens to prevent tuberculosis in adults with HIV infection. publication-title: N Engl J Med – volume: 12 start-page: 2447 year: 1998 end-page: 2457 ident: r013 article-title: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. publication-title: AIDS – volume: 173 start-page: 922 year: 2006 end-page: 926 ident: r027 article-title: Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. publication-title: Am J Respir Crit Care Med – volume: 179 start-page: 1055 year: 2009 end-page: 1060 ident: r036 article-title: Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. publication-title: Am J Respir Crit Care Med – reference: Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press, 2000. – volume: 353 start-page: 1843 year: 1999 end-page: 1847 ident: r033 article-title: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. publication-title: Lancet – volume: 283 start-page: 1445 year: 2000 end-page: 1450 ident: r014 article-title: Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. publication-title: JAMA – volume: 360 start-page: 528 year: 2002 end-page: 534 ident: r019 article-title: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. publication-title: Lancet – volume: 137 start-page: 640 year: 2002 end-page: 647 ident: r015 article-title: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. publication-title: Ann Intern Med – volume: 148 start-page: 1541 year: 1993 end-page: 1546 ident: r016 article-title: Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. publication-title: Am Rev Respir Dis – volume: 168 start-page: 443 year: 2003 end-page: 447 ident: r010 article-title: Use of isoniazid for latent tuberculosis infection in a public health clinic. publication-title: Am J Respir Crit Care Med – reference: Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011 ( ). – volume: 335 start-page: 126 year: 2008 end-page: 136 ident: r038 article-title: Update on rifampin and rifabutin drug interactions. publication-title: Am J Med Sci – volume: 173 start-page: 927 year: 2006 end-page: 931 ident: r006 article-title: The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. publication-title: Am J Respir Crit Care Med – volume: 153 start-page: 331 year: 1996 end-page: 335 ident: r024 article-title: Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. publication-title: Am J Respir Crit Care Med – reference: Global tuberculosis control 2010. Geneva: World Health Organization, 2010. – volume: 50 start-page: 289 year: 2001 ident: r029 publication-title: MMWR Morb Mortal Wkly Rep – ident: r012 doi: 10.1016/S0140-6736(97)06532-X – ident: r037 doi: 10.2165/00003088-200140050-00002 – volume: 7 start-page: S384 year: 2003 ident: r009 publication-title: Int J Tuberc Lung Dis – ident: r027 doi: 10.1164/rccm.200512-1953OC – ident: r001 – ident: r005 – ident: r014 doi: 10.1001/jama.283.11.1445 – ident: r006 doi: 10.1164/rccm.200510-1563OC – volume: 52 start-page: 735 year: 2003 ident: r031 publication-title: MMWR Morb Mortal Wkly Rep – ident: r011 doi: 10.1378/chest.09-0394 – ident: r016 doi: 10.1164/ajrccm/148.6_Pt_1.1541 – ident: r035 doi: 10.1016/S0002-9343(01)00695-7 – ident: r036 doi: 10.1164/rccm.200901-0153OC – ident: r002 doi: 10.1001/jama.273.3.220 – volume: 161 start-page: S221 year: 2000 ident: r003 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.161.supplement_3.ats600 – volume: 50 start-page: 733 year: 2001 ident: r030 publication-title: MMWR Morb Mortal Wkly Rep – volume: 150 start-page: 1355 year: 1994 ident: r018 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.150.5.7952564 – ident: r008 doi: 10.1056/NEJMsa031667 – ident: r028 doi: 10.1056/NEJMoa1005136 – volume: 153 start-page: 331 year: 1996 ident: r024 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.153.1.8542139 – ident: r026 doi: 10.1001/jama.295.10.1152 – volume: 3 start-page: 847 year: 1999 ident: r034 publication-title: Int J Tuberc Lung Dis – volume: 60 start-page: 555 year: 1982 ident: r007 publication-title: Bull World Health Organ – volume: 43 start-page: 2126 year: 1999 ident: r017 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.43.9.2126 – ident: r013 doi: 10.1097/00002030-199818000-00014 – ident: r020 doi: 10.1097/01.inf.0000214963.55217.9c – ident: r038 doi: 10.1097/MAJ.0b013e31814a586a – ident: r019 doi: 10.1016/S0140-6736(02)09742-8 – ident: r010 doi: 10.1164/rccm.200303-390OC – volume: 137 start-page: 640 year: 2002 ident: r015 publication-title: Ann Intern Med doi: 10.7326/0003-4819-137-8-200210150-00007 – ident: r025 doi: 10.1164/ajrccm/137.1.2 – volume: 19 start-page: 1 year: 1976 ident: r023 publication-title: Adv Tuberc Res – volume: 106 start-page: 357 year: 1972 ident: r032 publication-title: Am Rev Respir Dis doi: 10.1164/arrd.1972.106.3.357 – ident: r033 doi: 10.1016/S0140-6736(98)11467-8 – reference: 22150042 - N Engl J Med. 2011 Dec 8;365(23):2230-1 – reference: 22494127 - N Engl J Med. 2012 Apr 12;366(15):1447; author reply 1448 – reference: 22494128 - N Engl J Med. 2012 Apr 12;366(15):1447-8; author reply 1448
SSID	ssj0000149
Score	2.5855603
Snippet	Treatment of latent TB is an important public-health strategy, but 9 months of daily isoniazid (270 doses) poses challenges for compliance. In this study, 3... Treatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard regimen of... BackgroundTreatment of latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control and elimination. The current standard...
SourceID	proquest pubmed pascalfrancis crossref mms
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	2155
SubjectTerms	Adult Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Bacterial diseases Biological and medical sciences Directly Observed Therapy Drug Administration Schedule Drug Therapy, Combination Follow-Up Studies General aspects Hepatotoxicity HIV Human bacterial diseases Human immunodeficiency virus Humans Infections Infectious diseases Intention to Treat Analysis Isoniazid Isoniazid - administration & dosage Isoniazid - adverse effects Male Medical sciences Middle Aged Motivation Pharmacology. Drug treatments Prospective Studies Rifampin - administration & dosage Rifampin - adverse effects Rifampin - analogs & derivatives Risk Factors Self Administration Skin Tuberculosis Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis - prevention & control Tuberculosis and atypical mycobacterial infections Virus Latency
SummonAdditionalLinks	– databaseName: New England Journal of Medicine Current dbid: DCD link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDI54CXHh_RiDKQfEiYo1a5rkiAYIxEMIDYlblaapKNpStHYc-PU4bdgYaIJz3Cjyo_4cOzZCR1QDDJcB95hqMy8QYIoCogavcl9cMUVpXA2bYPf3_PlZPEyaJP3M4NPw1M6EzyV4KQut59Ei6JiwMxrOu-ff-kQ5nOuuilwzzV-fTzmf-cGgsKWQsgBupPUYi9k4s_I3l2v_Puk6WnWQEp_VOrCB5rTZRMt3Lmm-hW56IC-NwXrLlwLnKX7MUvlmq4SMxtIk-BowdyY_sgQDgsW3gD5NiXujWA_VqJ8XWYGvXcmW2UZPlxe97pXnZih4KuBB6RGhWFsnIfzF0raf2BfkQeL7SrGYkVCIlHDJY6qIJqFigA4II5rHRBIVaEF1ZwctmNzoPYSDNKYJwMVQ8cBGZUIL34aDCVWdpE1lA518MTdSrsG4nXPRj6pENw2jKQY10PGY_K3urDGLsAWSiox-HcwkmBLieDtCCfhixhuo-SXVyJloEQFOgnCKdWAVj1fBtmzCRBqdjywJwFvWEUCyW-vCZGuASjYLu__X4ZpopbqGthUw_AAtlMORPkRL6r3MimGrUuNP-ZflsA priority: 102 providerName: Massachusetts Medical Society
Title	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
URI	http://dx.doi.org/10.1056/NEJMoa1104875 https://www.ncbi.nlm.nih.gov/pubmed/22150035 https://www.proquest.com/docview/910255738 https://www.proquest.com/docview/911937398
Volume	365
WOSCitedRecordID	wos000297731400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Health Management Database (Proquest) customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Nursing & Allied Health Source customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED7RDSFeGL_pBpUfEE9ES5w4tp_Q1m1igpaqKqhvkeM4ImhNSpPywF_P2XXL9lBeePmkKCcr8vl8n32XO4C3zCANV4kIuA55kEg0RYmnhsC5L6G5Zix3zSb4eCzmcznxuTmtT6vc7oluoy4abe_IT9GtIfvlsfiw_BnYplE2uOo7aPTg0BZJiF3m3uRW9SjPfv0Fki-xiS7_1DaabxS6vsRlGN5ySb3ForUJkqrFOSo3zS32s0_nha6O_vP7H8MjTz_J2Wa9PIF7pn4KD0Y-wP4MPs1Qt4agpXffW9KUZFqVamkzimpDVF2Qa-TnlfpdFQTZLvmMTLXuyGydm5Ve3zRt1ZJrn95VP4evV5ez4cfA91sIdCKSLqBS89AUKe54ZRgV9m_zpIgirXnOaSplSYUSOdPU0FRzZBKUUyNyqqhOjGQmfgEHdVObV0CSMmcFUstUi8Se4KSRkT06FkzHRchUH95vpzzTvhi57Ylxk7mgOEuzOxrqw7ud-HJThWOf4AD1l9Xmx2KvwB3V7oajjKLf5qIPJ1v9Zd6c22ynvD6Q3Vu0QxtcUbVp1lYEqTCPJYq83KyQv0Pj2rQR2-N_Dn0CD919tU2VEa_hoFutzRu4r391VbsaQI9Pv1mcc4cCUQyjARyeX44nU3y6GF4gjsKpw5lFOnL4xeFk4KzjDxPxBug
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQEXngWWQvEBOBE167Vj-4AQAqqu9iGEgtRbcBxHBHWTZZMFwX_iPzJOnKU9LLceOGc0UuJvZr7xTGYAnnGLNFwzGQgTioApNEWFWUPQhi9phOE8bZdNiPlcnp6qDzvwu_8XxrVV9j6xddRZZdwd-RGGNWS_YiRfL78FbmmUK672GzQ6VEzszx-YsdWvxu_weJ9Tevw-fnsS-KUCgWGSNQFVRoQ2i9Cs83CYuV-qWTYcGiNSQSOlciq1TLmhlkZGYLikglqZUk0Ns4rbEerdhSturJ7rIJyF8blpVZ5t-wsrP9ITKcaRW2xfaQy1rO1oPBcCdxeL2jVk6hrPJO-WaWxnu23UO771n32v23DT02vyprOHO7Bjy7twbeYbCO7BJEbsWoKerPlSkyonH4tcL13HVGmJLjMyxvyj0L-KjCCbJ1Nk4mVD4nVqV2Z9VtVFTca-fa3ch0-X8ir3Ya-sSvsQCMtTniF1joxkLkNVVg1dapxxM8pCrgfwsj_ixPhh627nx1nSFv15lFxAxABebMSX3ZSRbYKHiJektF8XWwUuQGmjjnKKvETIARz0eEm8u6qTDVgGQDZP0c-44pEubbV2Ikj1xUihyIMOkX9VI210FelH_1T9FK6fxLNpMh3PJwdwo72bd21B8jHsNau1fQJXzfemqFeHrVUR-HzZsPwD4eNYvw
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nj9MwEB3tLmjFhe-PsrD4AJyI2jh2bB8QQrtUVF2qFSrS3oLjOCJom5QmBcE_498xTpyyeyi3PXDuyFLqNzNv7OcZgOfcIg3XTAbCjETAFLqiwqohaNOXNMJwnrbDJsRsJs_O1OkO_O7fwjhZZR8T20CdVcadkQ8xrSH7FZEc5l4VcXo8frP8FrgBUu6itZ-m0SFkan_-wOqtfj05xq1-Qen43fzofeAHDASGSdYEVBkxslmMLp6Pwsw9r2ZZGBojUkFjpXIqtUy5oZbGRmDqpIJamVJNDbOK2wjX3YVrIkIQu0fqR-GFzlWeefvDK9_eE-nG0A25rzSmXdaqGy-kw93FonbiTF3j_uTdYI3tzLfNgONb__F_dxtuetpN3nZ-cgd2bHkX9j94YcE9mM4R05ZghGu-1KTKycci10unpCot0WVGJliXFPpXkRFk-eQEGXrZkPk6tSuzPq_qoiYTL2sr78OnK_mUB7BXVqV9BITlKc-QUsdGMle5KqtCVzJn3ETZiOsBvOq3OzG-CbubBXKetGIAHieX0DGAlxvzZdd9ZJvhIWInKe3XxVaDS7DaLEc5Rb4i5AAOeuwkPozVyQY4AyCbXzH-uEslXdpq7UywBBCRQpOHHTr_Lo100t1UP_7n0s9gH9GYnExm0wO40R7ZO7WQfAJ7zWptn8J1870p6tVh62AEPl81Kv8AfKlhPQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three+Months+of+Rifapentine+and+Isoniazid+for+Latent+Tuberculosis+Infection&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Sterling%2C+Timothy+R.&rft.au=Villarino%2C+M.+Elsa&rft.au=Borisov%2C+Andrey+S.&rft.au=Shang%2C+Nong&rft.date=2011-12-08&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=365&rft.issue=23&rft.spage=2155&rft.epage=2166&rft_id=info:doi/10.1056%2FNEJMoa1104875&rft.externalDBID=n%2Fa&rft.externalDocID=10_1056_NEJMoa1104875
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon